Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2022_LYSA_Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases
J Oncol Pharm Pract . 2022 Mar;28(2):453-456.
En savoir plus
Lysa
2022_LYSA_Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials
Blood . 2022 Mar 17;139(11):1684-1693.
En savoir plus
Lysa
2022_LYSA_A guide to ComBat harmonization of imaging biomarkers in multicenter studies
J Nucl Med . 2022 Feb;63(2):172-179.
En savoir plus
Lysa
2022_LYSA_Deep Learning approach to automatize TMTV calculation regardless of segmentation methodology for main FDG avid lymphomas
Diagnostics (Basel) . 2022 Feb 6;12(2):417.
En savoir plus
Lysa
2022_LYSA_Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
Hemasphere . 2022 Jan 10;6(2):e672.
En savoir plus
Lysa
2022_LYSA_Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study
Ann Hematol . 2022 Feb;101(2):317-332.
En savoir plus
Lysa
2022_LYSA_Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
Cancers (Basel) 2022 Mar 30;14(7):1761. doi: 10.3390/cancers14071761.
En savoir plus
Lysa
2022_LYSA_Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study
Cancer . 2022 Feb 1;128(3):519-528. doi: 10.1002/cncr.33938.
En savoir plus
Lysa
2022_LYSA_Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
J Clin Oncol . 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815.
En savoir plus
Lysa
2022_LYSA_Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
N Engl J Med . 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304.
En savoir plus
Lysa
2022_LYSA_Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA
DOI: 10.1182/bloodadvances.2022008524
En savoir plus
Lysa
2022_LYSA_Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials
DOI: 10.1111/bjh.18594
En savoir plus
Lysa
2022_LYSA_ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
DOI: 10.3324/haematol.2022.281442
En savoir plus
Lysa
2022_LYSA_Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials
DOI: 10.1007/s11764-022-01305-w
En savoir plus
Lysa
2022_LYSA_Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
DOI: 10.1111/bjh.18519
En savoir plus
Lysa
2022_LYSA_Molecular Monitoring of Lymphomas
DOI: 10.1146/annurev-pathol-050520-044652
En savoir plus
Lysa
2022_LYSA_European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System lymphoma (PCNSL)
DOI: 10.1093/neuonc/noac196
En savoir plus
Lysa
2022_LYSA_Application of The Lugano Classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2- Technical)
DOI: 10.2967/jnumed.122.264124
En savoir plus
Lysa
2022_LYSA_Application of The Lugano Classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1- Clinical)
DOI: 10.2967/jnumed.122.264106
En savoir plus
Lysa
2022_LYSA_Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011
doi: 10.3390/cancers15010053
En savoir plus
Lysa
2022_LYSA_Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France
DOI: 10.1016/j.eclinm.2022.101674
En savoir plus
Lysa
2022_LYSA_Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
DOI: 10.1038/s41375-022-01717-8
En savoir plus
Lysa
2022_LYSA_18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients
DOI: 10.2967/jnumed.121.263501
En savoir plus
Lysa
2022_LYSA_A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma
DOI: 10.1182/bloodadvances.2021006923
En savoir plus